Vice President, Regulatory Affairs
Caroline Diaz joined ReViral in September 2020 as Vice President, Regulatory Affairs. Prior to joining ReViral, Caroline was Vice President, Regulatory and Quality at Dova Pharmaceuticals based in Durham, NC. While at Dova, Caroline built the regulatory function from the ground up and led regulatory strategy development and implementation efforts for Doptelet® (avatrombopag), resulting in approvals for marketing in the US, EU and China – the first marketing approvals for the company.
Prior to her tenure at Dova, Caroline held various roles in regulatory affairs strategy and regulatory operations at UCB Inc., Chimerix Inc., and GlaxoSmithKline, and has worked across multiple therapeutic areas including antivirals, immunology, and hematology. Prior to her roles in regulatory affairs, Caroline began her career in pharma as a medicinal chemist in the drug discovery labs at GlaxoSmithKline, focused in the metabolic diseases therapeutic area.
Caroline holds a BS in chemistry from Hope College in Holland, Michigan, and an MA in organic chemistry from the University of North Carolina-Chapel Hill.